

General Information	
Ministerial Decision Type	Miscellaneous
Report Title	Amendment to the Prescribed List as of 1 June 2024
Minister	Social Security
Signatory	Minister
Lead Department	Strategic Policy, Planning and Performance (SP3)
Lead Directorate	Public Policy (SP3)
Ministerial Decision Summary: Public or <a href="#">Absolutely/Qualified</a> Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Date decision made if different to date 'Ministerial Decision Summary' signed.	Select date.
Report and Supplemental Report Details	
Report Author	Senior Policy Officer
Date of Report	13/05/2024
Supplementary Report Title <i>(If applicable)</i>	SD report May 2024
Supplementary Report Author <i>(If applicable)</i>	Prescribing Advisor
Date of Supplementary Report <i>(If applicable)</i>	13/05/2024
Ministerial Decision Report: Public or <a href="#">Absolutely/Qualified</a> Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Relevant Case/Application/URN <i>(Only complete if making a decision related to an appeal where appropriate or allowed under legislation/case/application)</i>	Insert Relevant Case/Application.
Relevant Proposition Number <i>(Only complete if presenting Comments or if lodging an Amendment)</i>	Insert P. number.
Relevant Scrutiny Report <i>(Only complete if presenting a ministerial response)</i>	Insert S.R. number.
Associated Law(s) and/or Subordinate Legislation	Health Insurance (Jersey) Law 1967
Action required if recommendation agreed	Department to take necessary action.

Resource Implications	There are additional financial and/or manpower implications. Further detail is included in the detail section of the report.
-----------------------	--

## Introduction

Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 June 2024.

## Recommendation

Other

Only insert text if 'Other' selected above.

The Minister accepted recommendations from the PBAC in respect of the following additions and deletions.

### 1. Additions

- Colecalciferol 25,000-unit and 50,000-unit capsules
- Doxylamine 10mg/Pyridoxine 10mg gastro-resistant tablets (Xonvea)
- Drospirenone 4mg tablets (Slynd)
- Leflunomide 10mg, 20mg tablets (generic only)
- Levonorgestrel 19.5mg intrauterine device (Kyleena)
- Levonorgestrel 52mcg Intrauterine device (Benilexa)
- Loperamide 2mg orodispersible tablets sugar free
- Magnesium aspartate 243mg (magnesium 10mmol) oral powder sachets (including sugar free) and Magnesium glycerophosphate (magnesium 97.2mg (4mmol)) chewable tablets sugar free
- Midodrine 2.5mg, 5mg, 10mg tablets
- Minoxidil Tablets 2.5mg, 10mg tablets
- Ondansetron 4mg and 8mg Orodispersible Films Sugar Free
- T-Safe 380A QL intrauterine contraceptive device

### 2. Deletions

- Colestipol 5g granules sachets sugar free
- Diazepam 2.5mg/1.25mL rectal solution tube
- Disopyramide 150mg capsules
- Exenatide 2mg powder and solvent for prolonged release suspension for injection pre-filled disposable devices
- Insulin isophane biphasic human 25/75 100units/ml suspension for injection 3ml cartridges and pre-filled disposable devices
- Ketovite tablets
- Loperamide 1mg/5ml oral solution sugar free
- Sterculia 62% / Frangula 8% granules 7g sachets gluten free (Normacol Plus)
- Sterculia 62% granules 7g sachets gluten free (Normacol)
- Torasemide 2.5mg tablets

### 3. **Further deletions effective from 1 September 2024**

- Acebutolol 400mg tablets
- Cefradine 250mg & 500mg capsules
- Cefuroxime 250mg & 750mg powder for solution for injection vials
- Cimetidine 800mg tablets
- Clomethiazole 192mg capsules and 157.5mg/5mL oral solution
- Co-danthramer 25mg/200mg/5ml & 75mg/1000mg/5ml oral suspension sugar free

- Cyclophosphamide 50mg tablets
- Dicycloverine 10mg/5ml oral solution
- Ephedrine hydrochloride 15mg tablets
- Flavoxate 200mg tablets
- Fludroxycortide 0.0125% cream & ointment
- Hydrogen peroxide 6% solution
- Hydrous ointment
- Hyoscine hydrobromide 600micrograms/1ml solution for injection ampoules
- Insulin isophane biphasic human 50/50 100units/ml suspension for injection 3ml cartridges
- Insulin lispro biphasic 25/75 100units/ml suspension for injection 10mL vial (Humalog Mix 25)
- Iron dextran 100mg/2ml solution for injection ampoules
- Iron sucrose Injection 100mg/5ml ampoules
- Ketovite liquid
- Lidocaine 10% spray sugar free
- Lofepamine 70mg/5ml oral suspension sugar free
- Megestrol 160mg tablets
- Minocycline 50mg tablets
- Moclobemide 150mg and 300mg tablets
- Nabumetone 500mg tablets
- Nimodipine 10mg/50ml solution for infusion vials
- Ondansetron 16mg suppositories
- Ondansetron 4mg, 8mg oral lyophilisates sugar free
- Ondansetron 4mg, 8mg orodispersible tablets
- Orphenadrine 50mg/5ml oral solution sugar free
- Pentazocine 25mg tablets
- Promazine 25mg & 50mg tablets, 50mg/5mL oral solution
- Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 200ml bottles
- Surgical spirit
- Temazepam 10mg/5ml oral solution sugar free
- Tolbutamide 500mg tablets
- Tolbutamide 500mg tablets
- Tranylcypramine 10mg tablets
- Zinc and castor oil ointment

#### **4. Further Deletions to be effective from 1 January 2025**

- Nitrazepam 5mg tablets
- Temazepam 10mg, 20mg tablets

#### **5. Items to be listed brand name only from 1 September 2024**

- All insulin products
- Carbamazepine
- Clenil (beclometasone inhaler)
- Fostair and Fostair NEXThaler (beclometasone / formoterol combination inhaler)
- Liraglutide injection for diabetes (Victoza) or weight management (Saxenda)
- Lithium citrate, lithium carbonate
- Semaglutide injection for diabetes (Ozempic) or weight management (Wegovy)
- Tacrolimus and ciclosporin

**Financial impact**

Financial analysis suggests the impact of these changes to the prescribed list is minimal most likely delivering a nominal cost reduction.